Tucatinib acts as an HER2 inhibitor, and in BT474 breast carcinoma cells, it effectively suppresses HER2 phosphorylation. Tucatinib inhibits AKT phosphorylation and induces apoptosis in BT474 cells, rendering it a viable cytotoxic agent for formulating antibody-drug conjugates (ADCs).
Usually ships within 24 hours.